



FOR IMMEDIATE RELEASE

Medgenics, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference in New York

Misgav, Israel and London, UK – September 3, 2009 – Medgenics (AIM: MEDU, MEDG), today announced that Dr. Andrew Pearlman, President and Chief Executive Officer, will present at the Rodman & Renshaw Conference on Thursday, September 10th from 5:20 to 5:45 in the Garrison Salon (5th Floor) at the New York Palace Hotel.

Dr. Andrew Pearlman, will also be available for one-on-one meetings with analysts and investors on Thursday, September 10th.

Medgenics recently announced the unparalleled attainment of 11+ months of sustained treatment in anemic patients receiving a single administration of the Company's EPODURE tissue based Biopump sustained protein therapy. Management will discuss these and other results from its current Phase I/II safety and efficacy trial of the EPODURE Biopump for providing sustained treatment of anemia in patients with chronic kidney disease, and the Company's long-term growth strategy.

ABOUT MEDGENICS:

Medgenics, Inc. is a clinical-stage biopharmaceutical company developing its unique tissue-based Biopump platform technology to provide sustained-action protein therapy for the treatment of a range of chronic diseases.

The Biopump is a toothpick sized sliver of the patient's own dermal tissue obtained under local anesthetic, that has been processed within 2 weeks to become a unit producing a selected protein for a specific clinical application. Injected under the skin, the Biopump produces and delivers the therapeutic protein to the patient for several months.

Medgenics currently has two products in development based on this technology:

- EPODURE – producing erythropoietin (EPO) to treat anemia
- INFRADURE – producing interferon-alpha (IFN-a) to treat Hepatitis-C

The Company's ongoing Phase I/II clinical trial for EPODURE in anemic patients continues to demonstrate proof of concept of the Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for up to six months or more, EPODURE Biopumps are already maintaining effective anemia treatment for more than 10 months in earliest patients in the ongoing study, even with the low dose administered.

Medgenics intends to develop its innovative products and bring them to market via multiple strategic partnerships with major pharmaceutical and/or medical device companies, starting with EPODURE and INFRADURE.

Medgenics plans to raise the requisite funds during 2009/10 to commence a Phase I/II trial of INFRADURE in Hepatitis-C patients in Israel during 2010. The Company hopes that partnering discussions will lead to collaboration also in the next stage of EPODURE development, likely to be a Phase IIb multicenter study in anemic patients.

Beyond these, Medgenics plans to develop and/or out-license a pipeline of future Biopump products targeting the large and rapidly growing global protein therapy market, which is forecast to reach US \$87 billion by 2010. Other potential areas include multiple sclerosis (interferon- β), hemophilia (Factor VIII), pediatric growth hormone deficiency (human growth hormone) and diabetes (insulin).

Founded in 2000, Medgenics is a US-incorporated company with major operations in Misgav, Israel. Medgenics was admitted to the London AIM in December 2007 (AIM: MEDG and AIM: MEDU).

www.medgenics.com

CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, business strategy, plans and objectives of management for future operations. These statements relate to future events, prospects, developments and strategies. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.

Investor Relations:

Grayling Global

Ms. Leslie Wolf-Creutzfeldt

646-284-9472

leslie.wolf-creutzfeldt@us.grayling.com